Reference is made to the stock exchange announcement made on 27 September 2024
with key information regarding the consolidation (reverse split) of the
Company's shares and the warrants issued by the Company pursuant to a
resolution made by the extraordinary general meeting held on 16 May 2024 (the
"Warrants"). The following information is provided in connection with the ex.
date for the consolidation (reverse split) of shares and Warrants:

Issuer name: Lifecare ASA

Ex. date: 1 October 2024

Type of corporate action: Consolidation (reverse split) of shares and Warrants

This information is published in accordance with the requirements of the
Continuing Obligations.

About Lifecare:

Lifecare is a clinical stage medical sensor company developing technology for
sensing and monitoring of various body analytes. Lifecare's main focus is to
bring the next generation of Continuous Glucose Monitoring ("CGM") systems to
market. Lifecare enables osmotic pressure as sensing principle, combined with
the ability to manipulate Nano-granular Tunnelling Resistive sensors ("NTR")
on the sensor body for read-out of pressure variations. Lifecare's sensor
technology is referred to as "Sencell" and is suitable for identifying and
monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.

Contacts
For further information, please contact:

Joacim Holter, CEO,  joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities
Trading Act, §5-12. The information was submitted for publication at
2024-10-01 07:00 CEST.